secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261706
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Rein Therapeutics' Phase 2 trial of LTI-03 for IPF
-----------------------------------------------------------------------------

- FDA lifted full clinical hold after Rein's Complete Response submission; agency confirmed all concerns resolved.
- Company expects to resume U.S. patient enrollment in late 2025 or early 2026 across ~20 clinical sites.
- Global Phase 2 RENEW trial to enroll up to 120 IPF patients; topline data expected in Q3 2026.
- LTI-03 aims to slow fibrosis and promote lung repair, per CEO Brian Windsor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525261706/0001193125-25-261706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525261706/d47241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer